

KIR9214A.A9A  
HL13  
DEB:CSE:HL:lab  
12/05/96



Available Copy 2 E 11/10/96

PATENT APPLICATION  
DOCKET NO.: KIR92-01A4

#5  
2 E  
1-22-97

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Marc Feldmann and Ravinder N. Maini

Serial No.: 08/690,775

Group Art Unit: 1208 ✓

Filed: August 1, 1996

Examiner:

For: ANTI-TNF ANTIBODIES AND METHOTREXATE IN THE TREATMENT OF AUTOIMMUNE DISEASE

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231	
on <u>12/5/96</u>	<u>[Signature]</u>
Date	Signature
<u>Lisa Bevere</u>	
Typed or printed name of person signing certificate	

DEC 18 1996

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

This Information Disclosure Statement is submitted:

- ☐ under 37 CFR 1.129(a), or  
(First/Second submission after Final Rejection)
- ☒ under 37 CFR 1.97(b), or  
(Within three months of filing national application; or date of entry of the national stage in international application; or before mailing date of first office action on the merits; whichever occurs last)
- ☐ under 37 CFR 1.97(c) together with either:
- ☐ a Certification under 37 CFR 1.97(e), as checked below, or
- ☐ a \$230.00 fee under 37 CFR 1.17(p), or  
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with:
- ☐ a Certification under 37 CFR 1.97(e), as checked below, and
- ☐ a petition under 37 CFR 1.97(d)(2), and
- ☐ a \$130.00 petition fee set forth in 37 CFR 1.17(i).  
(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

Certification Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Enclosed herewith is form PTO-1449:

- ☐ Copies of the cited references are enclosed.
- ☒ Copies of cited references are enclosed (AS3-AW3) except those submitted in prior application, U.S. Serial No. 08/607,419 (AW-AR3), and those entered in prior application, U.S. Serial No. 08/403,785 (AL-AN and AR-AV), and references that are not required to be submitted under 37 CFR 1.98.
- ☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.

Concise Explanation Requirement (non-English references):

- ☐ The "concise explanation" requirement for reference(s) \_\_\_\_\_ under 37 CFR 1.98(a)(3) is satisfied by:
  - ☐ the explanation provided on the attached sheet.
  - ☐ the explanation provided in the Specification.
  - ☐ submission of the enclosed International Search Report.
  - ☐ abstract.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- ☐ Enclosed is a check in the amount of \$\_\_\_\_\_.
- ☐ Please charge Deposit Account 08-0380 in the amount of \$\_\_\_\_\_.
- ☐ Two duplicate copies of this Statement are enclosed.
- ☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

By Helen Lee  
Helen Lee  
Attorney for Applicants  
Registration No.: 39,270  
Telephone: (617) 861-6240

Lexington, Massachusetts 02173  
Dated: December 5, 1996